Liability in the context of misdiagnosis of melanoma in Australia

Melody R Abikhair, Patrick D Mahar, Adrian R Cachia and John W Kelly
Med J Aust 2014; 200 (2): 119-121. || doi: 10.5694/mja13.10239
Published online: 3 February 2014

Malignant melanoma is a disease for which misdiagnosis may have very serious ramifications for both patients and clinicians. Given how uncertain and difficult the diagnosis of some melanomas can be, clinicians may well be apprehensive about their potential professional liability arising from claimed misdiagnosis or mismanagement of melanoma. A recent Supreme Court of New South Wales decision1 is one of few Australian cases to directly address this issue specifically in relation to melanoma. Coote v Dr Kelly exists in the context of recent High Court of Australia decisions relating to the common law of professional negligence in Australia. Therefore, it is important to examine the particular facts of the case, how it was decided and why, and whether the court’s decision can reasonably be reconciled with what is understood of melanoma diagnosis clinically and from evidence-based medicine as well as a subsequent appeal which resulted in an order for retrial. We emphasise the importance of early recognition of uncertainty in diagnosis and subsequent escalation, particularly where delayed diagnosis may affect survival. This article provides medical practitioners with a better understanding of the uncertainty inherent in the law regarding certain issues of causation in negligence cases, and gives some guidance on an appropriate standard of care in the diagnosis of melanoma.

Standard of care and breach of duty

Certain melanomas are inherently difficult to diagnose clinically, particularly those not fulfilling the classical ABCD criteria (asymmetry, border irregularity, colour variegation, and diameter > 6 mm).3 In one study, nodular, desmoplastic and ALM subtypes were not only associated with rapid and aggressive tumour growth but were also more likely to be clinically atypical.4 That is, they were more often amelanotic, symmetrical and elevated, with a regular border. Diagnostic features of these atypical melanomas are less effectively taught, and timely and accurate diagnosis presents a major challenge, particularly in the general practice setting.

Given the difficulties inherent in diagnosis, misdiagnosis of an atypical melanoma should not necessarily be considered to be a breach of a reasonable standard of care, especially given that GPs may see very few of these lesions during their careers. Whether a misdiagnosis constitutes a breach of duty of care is determined by a court on the basis of the admissible evidence, including expert peer professional opinion. In this case, the plaintiff’s evidence that there was pigmentation of the lesion at the initial presentation was critical in determining whether a breach of duty had occurred. In the absence of comprehensive clinical notes, it was difficult for the defendant to establish that there was no pigmentation at the initial presentation. All the clinicians involved in this case agreed that if there was pigmentation of the lesion, further investigation would have been warranted, as this might have indicated a diagnosis other than that of a plantar wart. The importance placed by the court on the presence or absence of pigmentation in determining the appropriate response of a reasonably competent practitioner is interesting and emphasised in the appeal judgment.5 It was largely based on the expert opinions provided. While the presence or absence of pigmentation may be an appropriate diagnostic clue, it is only one part of the broader clinical picture. The courts may tend to lend it excessive weight. Pigmentation alone should not dispose of the question of breach of duty of care. A more reliable clue to misdiagnosis may well be failed response to treatments that have been tried.

Repeated failed non-definitive treatments were continued by multiple clinicians, which allowed a significant amount of time to pass without the patient being referred to a clinician with peer-recognised specialist qualifications in the diagnosis and management of skin disease. On the evidence available, we consider that it was not the misdiagnosis per se that amounted to a breach of duty of care, but the lack of recognition of uncertainty and a failure to appropriately refer the patient or conduct further investigations once treatment failure became apparent. Definitive biopsy or escalation of care by referral to a specialist may each have averted the breach in this case.

From a clinical perspective, this reinforces the importance of accurate and precise documentation and personal communication with other clinicians. A change in presentation or a pattern of unsuccessful treatment, and hence uncertainty in diagnosis, can thereby be identified and acted on.

Causation and prognosis

The relationship between delay in diagnosis and poorer prognosis in progressive neoplastic disease may seem intuitive for many clinicians. The court’s decision on this point may therefore seem surprising. Indeed, the Court of Appeal rejected it.

The Breslow thickness of a melanoma at the time of removal is a major predictor of the likelihood of metastasis and therefore of overall prognosis.5 In Australia, the 10-year survival rate is 98% for lesions less than 0.76 mm thick but only 53% for lesions more than 3 mm thick; the outcome for people with distant metastasis is extremely poor (5-year survival rate, < 5%).6

Despite this, any direct relationship between delay in diagnosis and increased melanoma thickness remains controversial.6-9 It is recognised that melanomas vary widely in their rate of progression, particularly according to subtype, with certain subtypes such as nodular melanoma known to have a rapid vertical growth phase. One explanation for the apparent lack of a demonstrated relationship between diagnostic delay and tumour thickness is that tumour thickness at diagnosis may be more strongly related to the growth rate and biological aggressiveness of the tumour, rather than to the measured delay in diagnosis.9 Considering melanomas together as a homogeneous group, rather than as subtypes with widespread variability in rates of growth, has also been suggested to be a possible confounding factor for any measured association between thickness and delay in diagnosis.5 It therefore becomes difficult to retrospectively draw conclusions to determine the prognostic impact of misdiagnosis.

The court referred to the recent landmark High Court case of Tabet v Gett,10 where a claim of negligence resulting only in a loss of a chance of a better medical outcome was rejected. Tabet v Gett has authoritatively settled the point that the defendant’s negligence must be proven, on the balance of probabilities, to be the cause of the poorer outcome for the patient, compared with the expected outcome had the breach of duty not occurred. A loss of a chance of a better outcome is not of itself sufficient for a claim in negligence to succeed.

In general, in Australia, for there to be factual causation, it is necessary to prove that the harm to the plaintiff would not have occurred without the defendant’s breach. In Coote v Dr Kelly, the breach by the defendant was effectively that of misdiagnosing melanoma and delaying targeted treatment. The key question therefore became whether it could be proven that a difference existed between the prognosis for the patient at the time of the first presentation and the prognosis at the time that the melanoma was eventually diagnosed, and whether this difference was caused by the actions of his GP.

Much of the evidence relied on the interpretation by expert witnesses of epidemiological studies used for determining possible prognosis. The purpose of these studies is not to establish likely prognosis or to determine retrospective prognosis in any particular case. As a consequence, on the balance of probabilities, the first-instance court determined it was not proven that metastasis had not already occurred and, at the time of his initial presentation in 2009, this particular patient may have already had a poor prognosis.

The Court of Appeal expressly rejected the proposition that epidemiological studies cannot provide evidence sufficient to prove causation on the balance of probabilities of loss in an individual case. We respectfully agree with the Court of Appeal and strongly caution the medical profession against relying on an assertion (supported at first instance) that epidemiological evidence is incapable of supporting a legal finding of causation in any individual case. It is so capable. “There is nothing in Tabet v Gett . . . standing in the way of such a conclusion”.11

Melanomas with rapid vertical growth phases and aggressive histological features may have vertical progression rates > 0.5 mm in thickness per month4 and, in these cases, it is even more likely that delay in diagnosis may lead to a significant decline in prognosis. The importance of accurate and timely diagnosis of such lesions, in order to capitalise on a potentially short window of opportunity for improved prognosis, is a clinical imperative granted additional legal force by the recent Court of Appeal findings.

Provenance: Not commissioned; externally peer reviewed.

  • Melody R Abikhair1
  • Patrick D Mahar2,3
  • Adrian R Cachia4
  • John W Kelly5,6

  • 1 Department of Dermatology, Monash Medical Centre, Monash Health, Melbourne, VIC.
  • 2 Department of Medicine, St Vincent’s Hospital, University of Melbourne, Melbourne, VIC.
  • 3 Department of Dermatology, St Vincent’s Hospital, St Vincent’s Health, Melbourne, VIC.
  • 4 Skin and Cancer Foundation Australia, Sydney, NSW.
  • 5 Victorian Melanoma Service, The Alfred Hospital, Alfred Health, Melbourne, VIC.
  • 6 Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC.

Competing interests:

No relevant disclosures.

  • 1. Coote v Dr Kelly [2012] NSWSC 219.
  • 2. Coote v Kelly (2013) NSWCA 357.
  • 3. Friedman RJ, Rigel DS, Kopf AW. Early detection of malignant melanoma: the role of physician examination and self-examination of the skin. CA Cancer J Clin 1985; 35: 130-151.
  • 4. Liu W, Dowling JP, Murray WK, et al. Rate of growth in melanomas, characteristics and associations of rapidly growing melanomas. Arch Dermatol 2006; 142: 1551-1558.
  • 5. Marks R. The changing incidence and mortality of melanoma in Australia. Recent Results Cancer Res 2002; 160: 113-121.
  • 6. Baade PD, English DR, Youl PH, et al. The relationship between melanoma thickness and time to diagnosis in a large population-based study. Arch Dermatol 2006; 142: 1422-1427.
  • 7. Krige JEJ, Isaacs S, Hudson DA, et al. Delay in the diagnosis of cutaneous malignant melanoma. A prospective study in 250 patients. Cancer 1991; 68: 2064-2068.
  • 8. Richard MA, Grob JJ, Avril MF, et al. Delays in diagnosis and melanoma prognosis (II): the role of doctors. Int J Cancer 2000; 89: 280-285.
  • 9. Richard MA, Grob JJ, Avril MF, et al. Melanoma and tumour thickness, challenges of early diagnosis. Arch Dermatol 1999; 135: 269-274.
  • 10. Tabet v Gett [2010] HCA 12.
  • 11. Coote v Kelly (2013) NSWCA 357: 64.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.